Dynamic changes in the regulatory T-cell heterogeneity and function by murine IL-2 mutein

Daniel R Lu1, Hao Wu2, Ian Driver1

  • 1Genome Analysis Unit, Amgen Research, Amgen Inc, South San Francisco, CA, USA.

Life Science Alliance
|April 10, 2020
PubMed
Summary

Interleukin-2 mutein (IL-2M) therapy expands regulatory T cell (Treg) subsets, revealing distinct transcriptional profiles and enhanced suppressive functions. This approach offers potential for treating autoimmune and inflammatory diseases.